Rationale: New regimens to shorten tuberculosis treatment and manage patients with drug-
resistant tuberculosis who are infected with HIV are urgently needed. Experimental and …

New regimens based on 2 or more novel agents are sought to shorten or to simplify
treatment of tuberculosis (TB), including drug-resistant forms. Prior studies showed that the …

Background New anti-tuberculosis regimens that are shorter, simpler, and less toxic than
those that are currently available are needed as part of the global effort to address the …

Novel regimens combining bedaquiline and pretomanid with either linezolid (BPaL regimen)
or moxifloxacin and pyrazinamide (BPaMZ regimen) shorten the treatment duration needed …

The 2-year follow-up results for a randomized placebo-controlled study of 47 patients with
multidrug-resistant pulmonary tuberculosis treated with either the new diarylquinoline …

Acquired drug resistance by Mycobacterium tuberculosis (MTB) may result in treatment
failure and death. Bedaquiline was recently approved for the treatment of multidrug-resistant …

Background New drugs, but also shorter, better-tolerated regimens are needed to tackle the
high global burden of tuberculosis complicated by drug resistance and retroviral disease …

Background Bedaquiline and delamanid are newly available drugs for treating multidrug-
resistant tuberculosis (MDR-TB); however, there are limited data guiding their use and no …

Bedaquiline is a new antituberculosis agent targeting ATP synthase. This randomized,
double-blinded study enrolling 68 sputum smear-positive pulmonary tuberculosis patients …

Background Bedaquiline (Sirturo, TMC207), a diarylquinoline that inhibits mycobacterial
ATP synthase, has been associated with accelerated sputum-culture conversion in patients …